JPM26: Boost in Biotech M&A, Emergence of 'New' Biogen, and Merck's Ambitious $70B Goal

JPM26: Boost in Biotech M&A, Emergence of ‘New’ Biogen, and Merck’s Ambitious $70B Goal

JPM26: Boost in Biotech M&A, Emergence of 'New' Biogen, and Merck's Ambitious $70B Goal